SeaStar Medical is trading up 5.82% at $3.82, with no confirmed catalyst identified for the October 12, 2026 move.
- The latest notable company news was the FDA’s October 7 Breakthrough Device Designation for its SCD therapy in adult sepsis; available reporting does not establish it as the cause of the gain.
- Major indexes were mixed, offering no clear broad-market explanation for the move.